IN THE SECTION on Dermatology of the American Medical Association (AMA), we try to have a diversified program. Papers are accepted which deal with new drug evaluations, and it is always hoped that these are controlled studies. New or improved treatment approaches will be given a place on the program. An attempt is made to appeal to clinicians as well as basic science investigators in the field of dermatology. A rather large number of papers are reviewed and it is our purpose to try to judge these on quality as best possible. We also endeavor not to overbalance the program with a single individual or institution. National geographic distribution is taken into consideration with all papers. The section feels that this meeting gives another opportunity for the relatively unknown individual to present his work for review.